KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Pacific Biosciences Of California (PACB) over the last 14 years, with Q3 2025 value amounting to $1.0 million.

  • Pacific Biosciences Of California's Other Accumulated Expenses rose 2835.25% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 2835.25%. This contributed to the annual value of $3.2 million for FY2024, which is 6127.79% down from last year.
  • Per Pacific Biosciences Of California's latest filing, its Other Accumulated Expenses stood at $1.0 million for Q3 2025, which was up 2835.25% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Pacific Biosciences Of California's Other Accumulated Expenses registered a high of $8.3 million during Q4 2023, and its lowest value of $783000.0 during Q3 2024.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $4.6 million (2022), whereas its average is $4.4 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first soared by 40119.86% in 2021, then crashed by 8485.49% in 2024.
  • Quarter analysis of 5 years shows Pacific Biosciences Of California's Other Accumulated Expenses stood at $5.8 million in 2021, then rose by 25.59% to $7.2 million in 2022, then increased by 15.11% to $8.3 million in 2023, then tumbled by 61.28% to $3.2 million in 2024, then crashed by 68.83% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $2.6 million for Q2 2025, and $5.6 million during Q1 2025.